Cullinan Therapeutics Reports Clinical Data And Outlines Global Clinical Development Plans For CLN-978, CD19xCD3 T Cell Engager, And Velinotamig, BCMAxCD3 T Cell Engager

Benzinga Newsdesk www.benzinga.com Neutral 92.3%

Neg 0% Neu 92.3% Pos 0%

Comments

No comments yet. Be the first!